[
  {
    "objectID": "research_forum/ICARUS/index.html",
    "href": "research_forum/ICARUS/index.html",
    "title": "ICARUS",
    "section": "",
    "text": "Event\nSociety of Cutaneous Oncology Research Forum\n\n\nOverview & Learning Objectives\n\nWe review the hypothesis, rationale and schema for ICARUS, an immunoprevention trial for patients with high-risk CSCC\n\n\n\nPresentation Slides\n\nTo view the slides for this presentation, please click here"
  },
  {
    "objectID": "research_forum/Art of the Review/index.html",
    "href": "research_forum/Art of the Review/index.html",
    "title": "To Accept, Revise or Reject - The Art of the Review",
    "section": "",
    "text": "Event\nSociety of Cutaneous Oncology Research Forum\n\n\nOverview & Learning Objectives\n\nWe review different approaches to the scientific review process"
  },
  {
    "objectID": "joco.html",
    "href": "joco.html",
    "title": "Journal of Cutaneous Oncology",
    "section": "",
    "text": "About the Journal\nThe Journal of Cutaneous Oncology (JoCO) is an open access journal whose scope is specific to skin cancer. Currently we publish a regular “Perspectives on the Science”, in which we provide commentary on publications reviewed in our multi-institutional SoCO Journal Club. The comments in this article represent the views of the authors of this Perspectives on the Science piece. It does not represent views of any other members of SoCO or the affiliated institutions.\n\n\nCurrent Issue\nPlease see our latest issue."
  },
  {
    "objectID": "jc.html#articles-1",
    "href": "jc.html#articles-1",
    "title": "Journal Club",
    "section": "2024 Articles",
    "text": "2024 Articles\n\n\n\n\n\n\nJanuary - February 2024\n\n\n\n\n\nFebruary\nDeCamp, Matthew, Julie Ressalam, Hillary D. Lum, Elizabeth R. Kessler, Dragana Bolcic-Jankovic, Vinay Kini, and Eric G. Campbell. 2023. “Ethics and Medical Aid in Dying: Physicians’ Perspectives on Disclosure, Presence, and Eligibility.” Journal of Law, Medicine & Ethics 51 (3): 641–50. DOI: 10.1017/jme.2023.1001\n\nJanuary\nMcEvoy, Aubriana M., Daniel S. Hippe, Kristina Lachance, Song Park, Kelsey Cahill, Mary Redman, Ted Gooley, Michael W. Kattan, and Paul Nghiem. 2023. “Merkel Cell Carcinoma Recurrence Risk Estimation Is Improved by Integrating Factors Beyond Cancer Stage: A Multivariable Model and Web-Based Calculator.” Journal of the American Academy of Dermatology, November. https://doi.org/10.1016/j.jaad.2023.11.020."
  },
  {
    "objectID": "jc.html#articles-2",
    "href": "jc.html#articles-2",
    "title": "Journal Club",
    "section": "2023 Articles",
    "text": "2023 Articles\n\n\n\n\n\n\nJanuary - December 2023\n\n\n\n\n\n\nDecember\nGross, Neil D, David M Miller, Nikhil I Khushalani, Vasu Divi, Emily S Ruiz, Evan J Lipson, Friedegund Meier, et al. 2023. “Neoadjuvant Cemiplimab and Surgery for Stage IIIV Cutaneous Squamous-Cell Carcinoma: Follow-up and Survival Outcomes of a Single-Arm, Multicentre, Phase 2 Study.” The Lancet Oncology 24 (11): 1196–1205. https://doi.org/10.1016/s1470-2045(23)00459-x.\n\n\nNovember\nBeal, Brandon T., Jeremy Udkoff, Leora Aizman, Jeremy Etzkorn, John A. Zitelli, Christopher J. Miller, Thuzar M. Shin, Joseph F. Sobanko, and David G. Brodland. 2023. “Outcomes of Invasive Melanoma of the Head and Neck Treated with Mohs Micrographic Surgery A Multicenter Study.” Journal of the American Academy of Dermatology 89 (3): 544–50. https://doi.org/10.1016/j.jaad.2022.12.038.\n\n\nSeptember\nVanderWalde, Ari, Shay L. Bellasea, Kari L. Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, et al. 2023. “Ipilimumab with or Without Nivolumab in PD-1 or PD-L1 Blockade Refractory Metastatic Melanoma: A Randomized Phase 2 Trial.” Nature Medicine, August. https://doi.org/10.1038/s41591-023-02498-y.\n\n\nAugust\nBecker, Jürgen C, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian Haferkamp, Lisa Zimmer, et al. 2023. “Adjuvant Immunotherapy with Nivolumab Versus Observation in Completely Resected Merkel Cell Carcinoma (ADMEC-O): Disease-Free Survival Results from a Randomised, Open-Label, Phase 2 Trial.” The Lancet, July. https://doi.org/10.1016/s0140-6736(23)00769-9.\n\n\nJuly\nDieng, Mbathio, Sarah J. Lord, Robin M. Turner, Omgo E. Nieweg, Alexander M. Menzies, Robyn P. M. Saw, Andrew J. Einstein, et al. 2022. “The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.” Annals of Surgical Oncology 29 (5): 2871–81. https://doi.org/10.1245/s10434-021-11231-3.\n\n\nJune\nMangione, Carol M., Michael J. Barry, Wanda K. Nicholson, David Chelmow, Tumaini Rucker Coker, Esa M. Davis, Katrina E. Donahue, et al. 2023. “Screening for Skin Cancer.” JAMA 329 (15): 1290. https://doi.org/10.1001/jama.2023.4342.\n\n\nMay\nDrobni, Zsofia D., Raza M. Alvi, Jana Taron, Amna Zafar, Sean P. Murphy, Paula K. Rambarat, Rayma C. Mosarla, et al. 2020. “Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.” Circulation 142 (24): 2299–2311. https://doi.org/10.1161/circulationaha.120.049981.\n\n\nApril\nPatel, Sapna P., Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, et al. 2023. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine 388 (9): 813–23.\n\n\nMarch\nAllen, Nicholas C., Andrew J. Martin, Victoria A. Snaidr, Renee Eggins, Alvin H. Chong, Pablo Fernandéz-Peñas, Douglas Gin, et al. 2023. “Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.” New England Journal of Medicine 388 (9): 804–12. https://doi.org/10.1056/nejmoa2203086.\n\n\nFebruary\nAscierto, Paolo A, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, et al. 2023. “Overall Survival with First-Line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study.” The Lancet Oncology 24 (1): 33–44. https://doi.org/10.1016/s1470-2045(22)00687-8.\n\n\nJanuary\nRohaan, Maartje W., Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, et al. 2022. “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.” New England Journal of Medicine 387 (23): 2113–25. https://doi.org/10.1056/nejmoa2210233."
  },
  {
    "objectID": "jc.html#articles-3",
    "href": "jc.html#articles-3",
    "title": "Journal Club",
    "section": "2022 Articles",
    "text": "2022 Articles\n\n\n\n\n\n\nJanuary - December 2022\n\n\n\n\n\n\nDecember\nAmaria, Rodabe N., Michael Postow, Elizabeth M. Burton, Michael T. Tezlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, et al. 2022. “Neoadjuvant Relatlimab and Nivolumab in Resectable Melanoma.” Nature 611 (7934): 155–60. https://doi.org/10.1038/s41586-022-05368-8.\n\n\nNovember\nKim, Sungjune, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire Verschraegen, Ram Thapa, Matthew Mills, et al. 2022. “Combined Nivolumab and Ipilimumab with or Without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma: A Randomised, Open Label, Phase 2 Trial.” The Lancet 400 (10357): 1008–19. https://doi.org/10.1016/s0140-6736(22)01659-2.\n\n\nOctober\nGross, Neil D., David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, et al. 2022. “Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.” New England Journal of Medicine387 (17): 1557–68. https://doi.org/10.1056/nejmoa2209813.\n\n\nAugust\nReijers, Irene L. M., Alexander M. Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, Noëlle M. J. van den Heuvel, Robyn P. M. Saw, Thomas E. Pennington, et al. 2022. “Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial.” Nature Medicine 28 (6): 1178–88. https://doi.org/10.1038/s41591-022-01851-x.\n\n\nJuly\nRuiz, Emily S., Kylee J. B. Kus, Timothy D. Smile, Fadi Murad, Guohai Zhou, Evelyn O. Ilori, Jonathan D. Schoenfeld, et al. 2022. “Adjuvant Radiation Following Clear Margin Resection of High T-Stage Cutaneous Squamous Cell Carcinoma Halves the Risk of Local and Locoregional Recurrence: A Dual-Center Retrospective Study.” Journal of the American Academy of Dermatology 87 (1): 87–94. https://doi.org/10.1016/j.jaad.2022.03.044.\n\n\nJune\nLiu, Kevin X., Michael G. Milligan, Jonathan D. Schoenfeld, Roy B. Tishler, Andrea K. Ng, Phillip M. Devlin, Elliott Fite, et al. 2022. “Characterization of Clinical Outcomes After Shorter Course Hypofractionated and Standard-Course Radiotherapy for Stage I-III Curatively-Treated Merkel Cell Carcinoma.” Radiotherapy and Oncology 173 (August): 32–40. https://doi.org/10.1016/j.radonc.2022.05.012.\n\n\nMay\nLuke, Jason J, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, et al. 2022. “Pembrolizumab Versus Placebo as Adjuvant Therapy in Completely Resected Stage IIB or IIC Melanoma (KEYNOTE-716): A Randomised, Double-Blind, Phase 3 Trial.” The Lancet 399 (10336): 1718–29. https://doi.org/10.1016/s0140-6736(22)00562-1.\n\n\nApril\nQian, David C, Troy Kleber, Brianna Brammer, Karen M Xu, Jeffrey M Switchenko, James R Janopaul-Naylor, Jim Zhong, et al. 2021. “Effect of Immunotherapy Time-of-Day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-Matched Analysis of a Single-Centre, Longitudinal Study.” The Lancet Oncology 22 (12): 1777–86. https://doi.org/10.1016/s1470-2045(21)00546-5.\n\n\nMarch\nMcEvoy, Aubriana M., Kristina Lachance, Daniel S. Hippe, Kelsey Cahill, Yasman Moshiri, Christopher W. Lewis, Neha Singh, et al. 2022. “Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis.” JAMA Dermatology 158 (4): 382. https://doi.org/10.1001/jamadermatol.2021.6096.\n\n\nFebruary\nTawbi, Hussein A., Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, et al. 2022. “Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma.” New England Journal of Medicine 386 (1): 24–34. https://doi.org/10.1056/nejmoa2109970.\n\n\nJanuary\nPostow, Michael A., Debra A. Goldman, Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, James W. Smithy, et al. 2022. “Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).” Journal of Clinical Oncology40 (10): 1059–67. https://doi.org/10.1200/jco.21.01570."
  },
  {
    "objectID": "jc.html#articles-4",
    "href": "jc.html#articles-4",
    "title": "Journal Club",
    "section": "2021 Articles",
    "text": "2021 Articles\n\n\n\n\n\n\nJanuary - December 2021\n\n\n\n\n\n\nDecember\nHarms, Paul W., Monique E. Verhaegen, Kevin Hu, Steven M. Hrycaj, May P. Chan, Chia-Jen Liu, Marina Grachtchouk, Rajiv M. Patel, Aaron M. Udager, and Andrzej A. Dlugosz. 2021. “Genomic Evidence Suggests That Cutaneous Neuroendocrine Carcinomas Can Arise from Squamous Dysplastic Precursors.” Modern Pathology 35 (4): 506–14. https://doi.org/10.1038/s41379-021-00928-1.\n\n\nNovember\nTawbi, Hussein A, Peter A Forsyth, F Stephen Hodi, Christopher D Lao, Stergios J Moschos, Omid Hamid, Michael B Atkins, et al. 2021. “Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients with Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).” Neuro-Oncology 23 (11): 1961–73. https://doi.org/10.1093/neuonc/noab094.\n\n\nOctober\nHsueh, Eddy C., James R. DeBloom, Jonathan H. Lee, Jeffrey J. Sussman, Kyle R. Covington, Hillary G. Caruso, Ann P. Quick, Robert W. Cook, Craig L. Slingluff, and Kelly M. McMasters. 2021. “Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.” JCO Precision Oncology, no. 5 (November): 589–601. https://doi.org/10.1200/po.20.00119.\n\n\nSeptember\nWilmas, Kelly M., Wesley B. Garner, Matthew T. Ballo, Susan L. McGovern, and Deborah F. MacFarlane. 2021a. “The Role of Radiation Therapy in the Management of Cutaneous Malignancies. Part I: Diagnostic Modalities and Applications.” Journal of the American Academy of Dermatology 85 (3): 539–48. https://doi.org/10.1016/j.jaad.2021.05.058. ———. 2021b. “The Role of Radiation Therapy in the Management of Cutaneous Malignancies. Part II: When Is Radiation Therapy Indicated?” Journal of the American Academy of Dermatology 85 (3): 551–62. https://doi.org/10.1016/j.jaad.2021.05.057.\n\n\nAugust\nPuebla-Tornero, Laura, Luis Antonio Corchete-Sánchez, Alberto Conde-Ferreirós, Natalia García-Sancha, Roberto Corchado-Cobos, Concepción Román-Curto, and Javier Cañueto. 2021. “Performance of Salamanca Refinement of the T3-AJCC8 Versus the Brigham and Women’s Hospital and Tübingen Alternative Staging Systems for High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 84 (4): 938–45. https://doi.org/10.1016/j.jaad.2020.12.020.\n\n\nJuly\nFarberg, Aaron S., Mary A. Hall, Leah Douglas, Kyle R. Covington, Sarah J. Kurley, Robert W. Cook, and Scott M. Dinehart. 2020. “Integrating Gene Expression Profiling into NCCN High-Risk Cutaneous Squamous Cell Carcinoma Management Recommendations: Impact on Patient Management.” Current Medical Research and Opinion 36 (8): 1301–7. https://doi.org/10.1080/03007995.2020.1763284.\n\n\nJune\nStratigos, Alexander J, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, et al. 2021. “Cemiplimab in Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy: An Open-Label, Multi-Centre, Single-Arm, Phase 2 Trial.” The Lancet Oncology 22 (6): 848–57. https://doi.org/10.1016/s1470-2045(21)00126-1.\n\n\nMay\nAndruska, Neal, Benjamin W. Fischer-Valuck, Lily Mahapatra, Randall J. Brenneman, Hiram A. Gay, Wade L. Thorstad, Ryan C. Fields, Kelly M. MacArthur, and Brian C. Baumann. 2021. “Association Between Surgical Margins Larger Than 1 Cm and Overall Survival in Patients With Merkel Cell Carcinoma.” JAMA Dermatology 157 (5): 540. https://doi.org/10.1001/jamadermatol.2021.0247.\n\n\nApril\nCho, Hyunje G., Karen Y. Kuo, Shufeng Li, Irene Bailey, Sumaira Aasi, Anne Lynn S. Chang, Anthony E. Oro, Jean Y. Tang, and Kavita Y. Sarin. 2018. “Frequent Basal Cell Cancer Development Is a Clinical Marker for Inherited Cancer Susceptibility.” JCI Insight 3 (15). https://doi.org/10.1172/jci.insight.122744.\n\n\nMarch\nMorgan, Frederick C., Emily Stamell Ruiz, Pritesh S. Karia, Robert J. Besaw, Victor A. Neel, and Chrysalyne D. Schmults. 2021. “Brigham and Women’s Hospital Tumor Classification System for Basal Cell Carcinoma Identifies Patients with Risk of Metastasis and Death.” Journal of the American Academy of Dermatology 85 (3): 582–87. https://doi.org/10.1016/j.jaad.2021.01.052.\n\n\nFebruary\nMorgan, Frederick C., Emily Stamell Ruiz, Pritesh S. Karia, Robert J. Besaw, Victor A. Neel, and Chrysalyne D. Schmults. 2020. “Factors Predictive of Recurrence, Metastasis, and Death from Primary Basal Cell Carcinoma 2 Cm or Larger in Diameter.” Journal of the American Academy of Dermatology 83 (3): 832–38.\n\n\nJanuary\nDanesh, Melissa J., Tyler D. Menge, Lydia Helliwell, Meera Mahalingam, and Abigail Waldman. 2020. “Adherence to the National Comprehensive Cancer Network Criteria of Complete Circumferential Peripheral and Deep Margin Assessment in Treatment of High-Risk Basal and Squamous Cell Carcinoma.” Dermatologic Surgery 46 (12): 1473–80. https://doi.org/10.1097/dss.0000000000002354."
  },
  {
    "objectID": "jc.html#articles-5",
    "href": "jc.html#articles-5",
    "title": "Journal Club",
    "section": "2020 Articles",
    "text": "2020 Articles\n\n\n\n\n\n\nJanuary - December 2020\n\n\n\n\n\n\nDecember\nTarabadkar, Erica S., Teresa Fu, Kristina Lachance, Daniel S. Hippe, Thomas Pulliam, Hannah Thomas, Janet Y. Li, et al. 2021. “Narrow Excision Margins Are Appropriate for Merkel Cell Carcinoma When Combined with Adjuvant Radiation: Analysis of 188 Cases of Localized Disease and Proposed Management Algorithm.” Journal of the American Academy of Dermatology 84 (2): 340–47. https://doi.org/10.1016/j.jaad.2020.07.079.\n\n\nNovember\nOwen, Joshua L, Nour Kibbi, Brandon Worley, Ryan C Kelm, Jordan V Wang, Christopher A Barker, Ramona Behshad, et al. 2019. “Sebaceous Carcinoma: Evidence-Based Clinical Practice Guidelines.” The Lancet Oncology 20 (12): e699–714. https://doi.org/10.1016/s1470-2045(19)30673-4.\n\n\nOctober\nSingh, Neha, Nora A. Alexander, Kristina Lachance, Christopher W. Lewis, Aubriana McEvoy, Gensuke Akaike, David Byrd, et al. 2021. “Clinical Benefit of Baseline Imaging in Merkel Cell Carcinoma: Analysis of 584 Patients.” Journal of the American Academy of Dermatology 84 (2): 330–39. https://doi.org/10.1016/j.jaad.2020.07.065.\n\n\nSeptember\nD’Arcy, Monica E, David Castenson, Charles F Lynch, Amy R Kahn, Lindsay M Morton, Meredith S Shiels, Ruth M Pfeiffer, and Eric A Engels. 2020. “Risk of Rare Cancers Among Solid Organ Transplant Recipients.” JNCI: Journal of the National Cancer Institute, May. https://doi.org/10.1093/jnci/djaa078.\n\n\nAugust\nSchauder, David M., Jinwan Kim, and Rajiv I. Nijhawan. 2020. “Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma.” JAMA Dermatology 156 (10): 1117. https://doi.org/10.1001/jamadermatol.2020.2327.\n\n\nJuly\nLobl, Marissa B., Dillon Clarey, Shauna Higgins, Adam Sutton, Laura Hansen, and Ashley Wysong. 2020. “Targeted Next-Generation Sequencing of Matched Localized and Metastatic Primary High-Risk SCCs Identifies Driver and Co-Occurring Mutations and Novel Therapeutic Targets.” Journal of Dermatological Science 99 (1): 30–43. https://doi.org/10.1016/j.jdermsci.2020.05.007.\n\n\nJune\nWysong, Ashley, Jason G. Newman, Kyle R. Covington, Sarah J. Kurley, Sherrif F. Ibrahim, Aaron S. Farberg, Anna Bar, et al. 2021. “Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 84 (2): 361–69. https://doi.org/10.1016/j.jaad.2020.04.088.\n\n\nMay\nTopalian, Suzanne L., Shailender Bhatia, Asim Amin, Ragini R. Kudchadkar, William H. Sharfman, Celeste Lebbé, Jean-Pierre Delord, et al. 2020. “Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.” Journal of Clinical Oncology 38 (22): 2476–87. https://doi.org/10.1200/jco.20.00201.\n\n\nMarch\nSekulic, Aleksandar, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, et al. 2017. “Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study.” BMC Cancer 17 (1). https://doi.org/10.1186/s12885-017-3286-5.\n\n\nFebruary\nRuiz, Emily Stamell, Shlomo A. Koyfman, Syril Keena T. Que, Jason Kass, and Chrysalyne D. Schmults. 2020. “Evaluation of the Utility of Localized Adjuvant Radiation for Node-Negative Primary Cutaneous Squamous Cell Carcinoma with Clear Histologic Margins.” Journal of the American Academy of Dermatology 82 (2): 420–29. https://doi.org/10.1016/j.jaad.2019.07.048."
  },
  {
    "objectID": "research_forum.html",
    "href": "research_forum.html",
    "title": "Research Forum",
    "section": "",
    "text": "In an effort to fulfill our missions of 1) supporting SoCO members in producing high-quality, reproducible science and 2) educating future generations of clinical oncologists and scientific investigators dedicated to skin cancer, the Society of Cutaneous Oncology supports an open forum for research discussions and presentations that convenes several times per year."
  },
  {
    "objectID": "research_forum.html#soco-research-forum-presentations",
    "href": "research_forum.html#soco-research-forum-presentations",
    "title": "Research Forum",
    "section": "SoCO Research Forum Presentations",
    "text": "SoCO Research Forum Presentations"
  },
  {
    "objectID": "slides.html#soco-research-forum",
    "href": "slides.html#soco-research-forum",
    "title": "Presentation Slides",
    "section": "SoCO Research Forum",
    "text": "SoCO Research Forum\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\n{background-image=“figures/title_slide.jpg”}\n\n\n\n\n\n\n\n2023\n\n\nSoCO Research Forum\n\n\n\n\nWe discuss the concept of a immunoprevention trial for CSCC\n\n\n\n\n\n\nMar 31, 2023\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "slides.html#aad-annual-meeting-2023",
    "href": "slides.html#aad-annual-meeting-2023",
    "title": "Presentation Slides",
    "section": "AAD Annual Meeting 2023",
    "text": "AAD Annual Meeting 2023\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMerkel Cell Carcinoma\n\n\n\n\nUpdates in Merkel Cell Carcinoma\n\n\n\n\n\n\nMar 18, 2023\n\n\n\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMerkel Cell Carcinoma\n\n\n\n\nPearls on the current concepts in diagnosis and management of uncommon cutaneous neoplasms\n\n\n\n\n\n\nMar 17, 2023\n\n\n\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nBCC\n\n\nCSCC\n\n\n\n\nPearls on the current concepts in diagnosis and management of operable non-melanoma skin cancer\n\n\n\n\n\n\nMar 17, 2023\n\n\n\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nPearls on the current concepts in peri-operative systemic therapy for high-risk melanoma\n\n\n\n\n\n\nMar 17, 2023\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "About SoCO",
    "section": "",
    "text": "The Society of Cutaneous Oncology (SoCO) is a collective of clinicians and investigators committed to improving outcomes in patients with skin cancer. Our mission is threefold: 1) to interpret evidence to help shape best practices, 2) to support members in producing high-quality reproducible science, and 3) educate future generations of clinical oncologists and scientific investigators dedicated to skin cancer. To fulfill those objectives the SoCO: 1) is the publisher of Journal of Cutaneous Oncology (JoCO), an open access journal whose scope is specific to skin cancer, 2) hosts a recurring monthly journal club and 3) supports an open forum for research discussions and presentations that convenes several times per year."
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#survey-questions",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#survey-questions",
    "title": "Society of Cutaneous Oncology",
    "section": "Survey Questions",
    "text": "Survey Questions\n\nREDCap Survey\nhttps://redcap.link/k77y3o9w"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#role",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#role",
    "title": "Society of Cutaneous Oncology",
    "section": "Role",
    "text": "Role"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience",
    "title": "Society of Cutaneous Oncology",
    "section": "CSCC Patient Care Experience",
    "text": "CSCC Patient Care Experience"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience-1",
    "title": "Society of Cutaneous Oncology",
    "section": "CSCC Patient Care Experience",
    "text": "CSCC Patient Care Experience"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience-2",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#cscc-patient-care-experience-2",
    "title": "Society of Cutaneous Oncology",
    "section": "CSCC Patient Care Experience",
    "text": "CSCC Patient Care Experience"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#overview",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#overview",
    "title": "Society of Cutaneous Oncology",
    "section": "Overview",
    "text": "Overview\n\n\n\nHypothesis\nRationale\nSchema\n\nSchema rationale\n\nEfficacy Assessment\n\nStatistical analysis\n\nSample Size Calculations\n\n\n\nEligibility Criteria\nTreatment Considerations\nAlternative Approach"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#hypothesis",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#hypothesis",
    "title": "Society of Cutaneous Oncology",
    "section": "Hypothesis",
    "text": "Hypothesis\n\nAnti-PD1 therapy will decrease the development of CSCC in high-risk patients with a history of multiple NMSCs"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#rationale",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#rationale",
    "title": "Society of Cutaneous Oncology",
    "section": "Rationale",
    "text": "Rationale\n\n\nEffective preventive strategies to mitigate CSCC are lacking\nAnti-PD1 therapy has shown to be effective in the neoadjuvant and advanced setting\nIntervention earlier in the disease journey will improve outcomes for patients at high-risk for morbid disease"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#schema---rationale",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#schema---rationale",
    "title": "Society of Cutaneous Oncology",
    "section": "Schema - Rationale",
    "text": "Schema - Rationale\n\n\nFeasibility\n\nPatients with ≥10 NMSCS (≥5 CSCCs) enriches for patients at high risk for recurrent disease\nActive surveillance for high-risk patients involves q3-6 month TSE (minimizes extra visits)\n\nBias\n\nPlacebo\n\nImportant to reduce bias when outcome is determined by physical exam & not scans\n\n\nEfficacy Assessment\n\nPrimary Endpoint: Rate of new KCC is an established endpoint (e.g.ONTRAC & ONTRANS (NEJM 2015/2023))"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#efficacy-assessment",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#efficacy-assessment",
    "title": "Society of Cutaneous Oncology",
    "section": "Efficacy Assessment",
    "text": "Efficacy Assessment\n\n\nPrimary endpoint\n\nRate of new CSCC\n\ncount data\n\n\nModeling count variables\n\nPoisson regression\nNegative binomial regression\n\nSimilar structure as Poisson, but has an extra parameter to model over-dispersion\n\nWhen the observed variance is higher than the variance of the theoretical model\n\nCommon in real-world data sets are populations are often heterogeneous and non-uniform"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#efficacy-assessment-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#efficacy-assessment-1",
    "title": "Society of Cutaneous Oncology",
    "section": "Efficacy Assessment",
    "text": "Efficacy Assessment\n\n\nlibrary(MASS)\n\nglm.nb(\n  formula = `New CSCCs` ~ Treatment + `Baseline CSCCs` + `CLL` + `Previous Radiation`,\n  init.theta = 0.75\n)"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#secondary-endpoints",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#secondary-endpoints",
    "title": "Society of Cutaneous Oncology",
    "section": "Secondary Endpoints",
    "text": "Secondary Endpoints\n\n\nNumber of new basal-cell carcinomas & actinic keratoses during the 12-month intervention period\nThe number of new non-melanoma skin cancers in the 6-month post intervention period\nSafety of anti-PDX as assessed by the numbers and types of adverse events"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Calculations",
    "text": "Sample Size Calculations\n\nConsiderations\n\nSample size will vary depending on:\n\nbaseline event rate\n\neffect size"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-1",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Calculations",
    "text": "Sample Size Calculations\n\nExample #1\n\n\nn <- ynegbinomsize(\n  r0=7.0, # event rate group 1 (Placebo)\n  r1=4.9, # event rate group 2 (Treatment with 30% rate reduction)\n  shape1=0.75, pi1=0.5, alpha=0.05, twosided=1, beta=0.2, \n  fixedfu=1, type=4, u=c(0.5,0.5,1), ut=c(0.5,1.0,1.5), \n  tfix=5, maxfu=1, tchange=1,ratec1=.1, ratec0=.1, eps=1.0e-03)\n\nTotal Sample Size: 254\n\nCalculating sample size based on using a Negative Binomial Regression Model (using NBDesign Package)."
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-2",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-2",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Calculations",
    "text": "Sample Size Calculations\n\nExample #2\n\n\nn <- ynegbinomsize(\n  r0=2.6, # event rate group 1 (Placebo)\n  r1=1.8, # event rate group 2 (Treatment with 30% rate reduction)\n  shape1=0.75, pi1=0.5, alpha=0.05, twosided=1, beta=0.2, \n  fixedfu=1, type=4, u=c(0.5,0.5,1), ut=c(0.5,1.0,1.5), \n  tfix=5, maxfu=1, tchange=1,ratec1=.1, ratec0=.1, eps=1.0e-03)\n\nTotal Sample Size: 299\n\nCalculating sample size based on using a Negative Binomial Regression Model (using NBDesign Package)."
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-3",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-3",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Calculations",
    "text": "Sample Size Calculations\n\nExample #3\n\n\nn <- ynegbinomsize(\n  r0=2.0, # event rate group 1 (Placebo)\n  r1=1.4, # event rate group 2 (Treatment with 30% rate reduction)\n  shape1=0.75, pi1=0.5, alpha=0.05, twosided=1, beta=0.2, \n  fixedfu=1, type=4, u=c(0.5,0.5,1), ut=c(0.5,1.0,1.5), \n  tfix=5, maxfu=1, tchange=1,ratec1=.1, ratec0=.1, eps=1.0e-03)\n\nTotal Sample Size: 348\n\nCalculating sample size based on using a Negative Binomial Regression Model (using NBDesign Package)."
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-4",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-calculations-4",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Calculations",
    "text": "Sample Size Calculations\n\nExample #4\n\n\nn <- ynegbinomsize(\n  r0=2.0, # event rate group 1 (Placebo)\n  r1=1.2, # event rate group 2 (Treatment with 40% rate reduction)\n  shape1=0.75, pi1=0.5, alpha=0.05, twosided=1, beta=0.2, \n  fixedfu=1, type=4, u=c(0.5,0.5,1), ut=c(0.5,1.0,1.5), \n  tfix=5, maxfu=1, tchange=1,ratec1=.1, ratec0=.1, eps=1.0e-03)\n\nTotal Sample Size: 172\n\nCalculating sample size based on using a Negative Binomial Regression Model (using NBDesign Package)."
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-parameters",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#sample-size-parameters",
    "title": "Society of Cutaneous Oncology",
    "section": "Sample Size Parameters",
    "text": "Sample Size Parameters"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#background-on-nmsc-incidence",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#background-on-nmsc-incidence",
    "title": "Society of Cutaneous Oncology",
    "section": "Background on NMSC Incidence",
    "text": "Background on NMSC Incidence\n\n\nRisk of subsequent NMSC is proportional to numbers of previously diagnosed skin cancers\nIn one study, the five year risk of developing another skin cancer was estimated at >60% for individuals with two previous skin cancers and at >90% for individuals with 4-5 previous skin cancers(Karagas 1992)\nIn ONTRAC, patients receiving placebo developed on average 2.4 NMSCs (0.7 CSCCs) in 12 months(Chen et al. 2015)\n\nInclusion: ≥2 NMSCs in the previous 5 years\nActual Baseline: 7.9 ± 8.0 NMSCs, 2.1 ± 3.5 CSCCs in Placebo\n\nIn ONTRANS, patients receiving placebo developed on average 2.7 NMSCs (1.9 CSCCs) in 12 months(Allen et al. 2023)\n\nInclusion: ≥2 NMSCs in the previous 5 years\nActual Baseline: 7.5 ± 7.6 NMSCs, 4.8 ± 5.6 CSCCs in Placebo"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#eligibility-criteria",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#eligibility-criteria",
    "title": "Society of Cutaneous Oncology",
    "section": "Eligibility Criteria",
    "text": "Eligibility Criteria\n\n\nInclusion\n\nAt least 10 NMSC, ≥5 CSCCs\nECOG 0, 1 or 2\n\nExclusion\n\nPrevious ICI\nActive pharmacological immunosuppression\nHIV with detectable viral loads (undetectable dz allowed)\nField treatment with the past 4 weeks\nNicotinamide use within the past 3 months"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#treatment-considerations",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#treatment-considerations",
    "title": "Society of Cutaneous Oncology",
    "section": "Treatment Considerations",
    "text": "Treatment Considerations"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-antibody-characteristics",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-antibody-characteristics",
    "title": "Society of Cutaneous Oncology",
    "section": "ICI Antibody Characteristics",
    "text": "ICI Antibody Characteristics\n\n\nFor most ICIs (except ipilimumab), there is no clear relationship between dose and efficacy or safety\nThe dose-response and exposure-response curves showed an obvious plateau, possilby implying that increasing doses do not contribute to tumor control"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-antibody-characteristics-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-antibody-characteristics-1",
    "title": "Society of Cutaneous Oncology",
    "section": "ICI Antibody Characteristics",
    "text": "ICI Antibody Characteristics\n\n\n\n\n  \n    \n      ICI Characteristics\n    \n    \n  \n  \n    \n      Target\n      Drug\n      Half-life\n      Dose\n      Schedule\n    \n  \n  \n    CTLA-4\nIpilimumab\n~15 days\n3 mg/kg\nq3 weeks\n    CTLA-4\nIpilimumab\n~15 days\n10 mg/kg\nq3 weeks\n    PD-1\nNivolumab\n~25 days\n240 mg\nq2 weeks\n    PD-1\nNivolumab\n~25 days\n480 mg\nq4 weeks\n    PD-1\nPembrolizumab\n~25 days\n200 mg\nq3 weeks\n    PD-1\nPembrolizumab\n~25 days\n400 mg\nq6 weeks\n    PD-1\nCemiplimab\n~19 days\n350 mg\nq3 weeks\n    PD-1\nRetinfanlimab\n~18 days\n500 mg\nq4 weeks\n    PD-L1\nAvelumab\n~4 days\n800 mg\nq2 weeks\n    PD-L1\nAtezolizumab\n~27 days\n840 mg\nq2 weeks\n    PD-L1\nAtezolizumab\n~27 days\n1200 mg\nq3 weeks\n    PD-L1\nAtezolizumab\n~27 days\n1680 mg\nq4 weeks\n    PD-L1\nDurvalumab\n~18 days\n10 mg/kg\nq2 weeks\n    PD-L1\nDurvalumab\n~18 days\n1500 mg\nq4 weeks"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-dose-response",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-dose-response",
    "title": "Society of Cutaneous Oncology",
    "section": "ICI Dose Response",
    "text": "ICI Dose Response\n\n\n\n\n  \n    \n      Dose-Efficacy\n    \n    \n  \n  \n    \n      Target\n      Drug\n      Indication\n      Dose\n      ORR (%)\n      PFS (% at 2 years)\n      G3-G4 toxicity (%)\n    \n  \n  \n    CTLA-4\nIpilimumab\nMelanoma\n0.3 mg/kg Q3W\n0\n2.7\n\n    CTLA-4\nIpilimumab\nMelanoma\n3 mg/kg Q3W\n4.2-19\n12.9\n15-27.3\n    CTLA-4\nIpilimumab\nMelanoma\n10 mg/kg Q3W\n11.1-15\n18.9\n31-34\n    PD-1\nNivolumab\nMelanoma\n0.1 mg/kg Q2W\n29-35\n40-41\n0-5\n    PD-1\nNivolumab\nMelanoma\n0.3 mg/kg Q2W\n19-28\n31-35\n0-3\n    PD-1\nNivolumab\nMelanoma\n1 mg/kg Q2W\n30-31\n45-51\n6-12\n    PD-1\nNivolumab\nNSCLC\n1 mg/kg Q2W\n3-6\n24-46\n15.2\n    PD-1\nNivolumab\nNSCLC\n3 mg/kg Q2W\n24-32\n40-41\n13.5\n    PD-1\nNivolumab\nNSCLC\n10 mg/kg Q2W\n18-20\n24-33\n13.6\n    PD-1\nNivolumab\nRCC\n0.3 mg/kg Q2W\n20\n30\n18.2\n    PD-1\nNivolumab\nRCC\n1 mg/kg Q2W\n24-28\n47-50\n12\n    PD-1\nNivolumab\nRCC\n2 mg/kg Q2W\n22\n30\n17\n    PD-1\nNivolumab\nRCC\n10 mg/kg Q2W\n31\n67\n13\n    PD-1\nPembrolizumab\nMelanoma\n2 mg/kg Q3W\n21-32.9\n45\n8-15\n    PD-1\nPembrolizumab\nMelanoma\n10 mg/kg Q2W\n33.7-52\n\n13.3-22.8\n    PD-1\nPembrolizumab\nMelanoma\n10 mg/kg Q3W\n26-35.9\n37\n3.6-15\n    PD-1\nPembrolizumab\nNSCLC\n2 mg/kg Q3W\n15-25\n\n13\n    PD-1\nPembrolizumab\nNSCLC\n10 mg/kg Q2W\n19.3-21\n\n9\n    PD-1\nPembrolizumab\nNSCLC\n10 mg/kg Q3W\n19.2-25\n\n9"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-dose-response-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#ici-dose-response-1",
    "title": "Society of Cutaneous Oncology",
    "section": "ICI Dose Response",
    "text": "ICI Dose Response\n\n\n\n\n  \n    \n      Dose-Efficacy\n    \n    \n  \n  \n    \n      Target\n      Drug\n      Indication\n      Dose\n      ORR (%)\n      PFS (% at 2 years)\n      G3-G4 toxicity (%)\n    \n  \n  \n    CTLA-4\nIpilimumab\nMelanoma\n0.3 mg/kg Q3W\n0\n2.7\n\n    CTLA-4\nIpilimumab\nMelanoma\n3 mg/kg Q3W\n4.2-19\n12.9\n15-27.3\n    CTLA-4\nIpilimumab\nMelanoma\n10 mg/kg Q3W\n11.1-15\n18.9\n31-34\n    PD-1\nNivolumab\nMelanoma\n0.1 mg/kg Q2W\n29-35\n40-41\n0-5\n    PD-1\nNivolumab\nMelanoma\n0.3 mg/kg Q2W\n19-28\n31-35\n0-3\n    PD-1\nNivolumab\nMelanoma\n1 mg/kg Q2W\n30-31\n45-51\n6-12\n    PD-1\nNivolumab\nNSCLC\n1 mg/kg Q2W\n3-6\n24-46\n15.2\n    PD-1\nNivolumab\nNSCLC\n3 mg/kg Q2W\n24-32\n40-41\n13.5\n    PD-1\nNivolumab\nNSCLC\n10 mg/kg Q2W\n18-20\n24-33\n13.6\n    PD-1\nNivolumab\nRCC\n0.3 mg/kg Q2W\n20\n30\n18.2\n    PD-1\nNivolumab\nRCC\n1 mg/kg Q2W\n24-28\n47-50\n12\n    PD-1\nNivolumab\nRCC\n2 mg/kg Q2W\n22\n30\n17\n    PD-1\nNivolumab\nRCC\n10 mg/kg Q2W\n31\n67\n13\n    PD-1\nPembrolizumab\nMelanoma\n2 mg/kg Q3W\n21-32.9\n45\n8-15\n    PD-1\nPembrolizumab\nMelanoma\n10 mg/kg Q2W\n33.7-52\n\n13.3-22.8\n    PD-1\nPembrolizumab\nMelanoma\n10 mg/kg Q3W\n26-35.9\n37\n3.6-15\n    PD-1\nPembrolizumab\nNSCLC\n2 mg/kg Q3W\n15-25\n\n13\n    PD-1\nPembrolizumab\nNSCLC\n10 mg/kg Q2W\n19.3-21\n\n9\n    PD-1\nPembrolizumab\nNSCLC\n10 mg/kg Q3W\n19.2-25\n\n9"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#alterative-approach",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#alterative-approach",
    "title": "Society of Cutaneous Oncology",
    "section": "Alterative Approach",
    "text": "Alterative Approach"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#inclusion-criteria",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#inclusion-criteria",
    "title": "Society of Cutaneous Oncology",
    "section": "Inclusion Criteria",
    "text": "Inclusion Criteria"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#open-icarus",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#open-icarus",
    "title": "Society of Cutaneous Oncology",
    "section": "Open ICARUS",
    "text": "Open ICARUS"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#inclusion-criteria-1",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#inclusion-criteria-1",
    "title": "Society of Cutaneous Oncology",
    "section": "Inclusion Criteria",
    "text": "Inclusion Criteria"
  },
  {
    "objectID": "slides/soco_research_forum/icarus_03_31_2023/index.html#references",
    "href": "slides/soco_research_forum/icarus_03_31_2023/index.html#references",
    "title": "Society of Cutaneous Oncology",
    "section": "References",
    "text": "References\n\n\n\n\n\n\nAllen, Nicholas C., Andrew J. Martin, Victoria A. Snaidr, Renee Eggins, Alvin H. Chong, Pablo Fernandéz-Peñas, Douglas Gin, et al. 2023. “Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.” New England Journal of Medicine 388 (9): 804–12. https://doi.org/10.1056/nejmoa2203086.\n\n\nChen, Andrew C., Andrew J. Martin, Bonita Choy, Pablo Fernández-Peñas, Robyn A. Dalziell, Catriona A. McKenzie, Richard A. Scolyer, et al. 2015. “A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.” New England Journal of Medicine 373 (17): 1618–26. https://doi.org/10.1056/nejmoa1506197.\n\n\nKaragas, Margaret R. 1992. “Risk of Subsequent Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Among Patients With Prior Skin Cancer.” JAMA: The Journal of the American Medical Association 267 (24): 3305. https://doi.org/10.1001/jama.1992.03480240067036."
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/volunteering_abroad_a_surgical_perspective/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/volunteering_abroad_a_surgical_perspective/index.html",
    "title": "Volunteering Abroad, A Surgical Perspective",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Volunteers Abroad: Beginners” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/update_in_advanced_melanoma_therapy/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/update_in_advanced_melanoma_therapy/index.html",
    "title": "Update in Advanced Melanoma Therapy",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “What’s New in the Management of Advanced Skin Cancer” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/management_of_operable_advanced_NMSC/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/management_of_operable_advanced_NMSC/index.html",
    "title": "Management of Operable Advanced NMSC",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “What’s New in the Management of Advanced Skin Cancer” Session\n\n\nOverview & Learning Objectives\n\nReview the work up for operable NMSC\n\nDiscuss the utility of SLNBx & imaging in CSCC\nDiscuss the role of GEP in CSCC\n\nReview the management of operable NMSC\n\nDiscuss the role of CPEMA and adjuvant therapy\nDiscuss the role of pre-operative systemic therapy for NMSC\n\n\n\n\nPresentations Slides\n\nTo view the slides for this presentation, please click here"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/multidisciplinary_management_of_melanoma_and_mcc/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/multidisciplinary_management_of_melanoma_and_mcc/index.html",
    "title": "Multidisciplinary Management of Melanoma and Merkel Cell Carcinoma",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Pearls from Complex Mohs” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/lessons_learned_from_resident_selection_and_recruitment/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/lessons_learned_from_resident_selection_and_recruitment/index.html",
    "title": "Lessons learned from resident selection and recruitment",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “DEI in GME: Thoughts and Considerations” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/update_on_the_latest_advances_in_treatment_of_melanoma/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/update_on_the_latest_advances_in_treatment_of_melanoma/index.html",
    "title": "Update on the Latest Advances in Treatment of Melanoma",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Updates in Cutaneous Oncology” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/how_can_we_improve_detection_and_reduce_unnecessary_biopsies_in_melanoma/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/how_can_we_improve_detection_and_reduce_unnecessary_biopsies_in_melanoma/index.html",
    "title": "How can we improve detection and reduce unnecessary biopsies: from dermoscopy to artificial intelligence to non-invasive molecular testing?",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Managing Melanoma” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/optimize_your_management_of_high-risk_cutaneous_SCCs/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/optimize_your_management_of_high-risk_cutaneous_SCCs/index.html",
    "title": "Respect the Dormant Beast: Optimize Your Management of High-risk Cutaneous SCCs",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Respect the Dormant Beast: Optimize Your Management of High-risk Cutaneous SCCs” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/updates_in_mcc/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/updates_in_mcc/index.html",
    "title": "Updates in Merkel Cell Carcinoma",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Updates in Cutaneous Oncology” Session\n\n\nOverview & Learning Objectives\n\nBrief overview of pathophysiology of Merkel cell carcinoma\n\nRecognize the use of Imaging and the Merkel cell polyoma virus serum antibody test in clinical practice\n\nDiscuss recently approved therapeutic strategies in MCC, including the use of Immune Checkpoint Inhibitors as primary treatment, as well as emerging strategies in the neo-adjuvant and adjuvant setting\n\n\n\nPresentation Slides\n\nTo view the slides for this presentation, please click here"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/exploring_neoadjuvant_immunotherapies_for_resectable_CSCC/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/exploring_neoadjuvant_immunotherapies_for_resectable_CSCC/index.html",
    "title": "Exploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma",
    "section": "",
    "text": "Med Learning Group TeleECHO. Event URL"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/exploring_neoadjuvant_immunotherapies_for_resectable_CSCC/index.html#overview",
    "href": "presentations/AAD_Annual_Meeting_2023/exploring_neoadjuvant_immunotherapies_for_resectable_CSCC/index.html#overview",
    "title": "Exploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma",
    "section": "Overview",
    "text": "Overview\nIn this live program we discuss how neoadjuvant immunotherapy fits into the treatment plan for many patients with surgically resectable cutaneous squamous cell carcinoma."
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/a_non-invasive_adhesive_patch_gene_expression_test_is_safe_and_cost_effective_for_melanoma_screening/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/a_non-invasive_adhesive_patch_gene_expression_test_is_safe_and_cost_effective_for_melanoma_screening/index.html",
    "title": "A non-invasive, adhesive patch gene expression test is safe and cost effective for melanoma screening: CON?",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “The 2023 Debates: Controversies in Dermatology” Session"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/management_of_high_risk_uncommon_cutaneous_neoplasms/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/management_of_high_risk_uncommon_cutaneous_neoplasms/index.html",
    "title": "Management of High Risk Uncommon Cutaneous Neoplasms",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “What’s New in the Management of Advanced Skin Cancer” Session\n\n\nOverview & Learning Objectives\n\nBrief overview of pathophysiology of Sebaceous Carcinoma, Dermatofibrosarcoma Protuberans and Merkel cell carcinoma\n\nRecognize the use of Imaging and the Merkel cell polyoma virus serum antibody test in clinical practice\n\nDiscuss recently approved therapeutic strategies in MCC, including the use of Immune Checkpoint Inhibitors as primary treatment, as well as emerging strategies in the neo-adjuvant and adjuvant setting\n\n\n\nPresentation Slides\n\nTo view the slides for this presentation, please click here\n\n\nTis site represents our opinions only. See our full Disclaimer and Terms of Use Agreement"
  },
  {
    "objectID": "presentations/AAD_Annual_Meeting_2023/perioperative_systemic_therapy_for_melanoma/index.html",
    "href": "presentations/AAD_Annual_Meeting_2023/perioperative_systemic_therapy_for_melanoma/index.html",
    "title": "How do we implement systemic therapy to reduce recurrence of high-risk melanomas: from neoadjuvant to adjuvant therapy?",
    "section": "",
    "text": "Event\nAmerican Academy of Dermatology Annual Meeting “Managing Melanoma” Session\n\n\nOverview & Learning Objectives\n\nReview the work up for high-risk melanoma\nReview the role of pre-operative systemic therapy in melanoma\nReview the role of post-operative systemic therapy in melanoma\n\n\n\nPresentation Slides\n\nTo view the slides for this presentation, please click here\n\n\nTis site represents our opinions only. See our full Disclaimer and Terms of Use Agreement"
  },
  {
    "objectID": "presentations/MCGI_2023/novel_approaches_to_ras_targeting/index.html",
    "href": "presentations/MCGI_2023/novel_approaches_to_ras_targeting/index.html",
    "title": "Novel Approaches to RAS Targeting",
    "section": "",
    "text": "Event\n2023 MCGI Forum\n\n\nOverview & Learning Objectives\n\nDiscussion of novel approaches to targeting RAS"
  },
  {
    "objectID": "presentations/SSO_2023/Intralesional_Treatments_for_Cancer/index.html",
    "href": "presentations/SSO_2023/Intralesional_Treatments_for_Cancer/index.html",
    "title": "Intralesional Treatments for Cancer",
    "section": "",
    "text": "Event\nSociety of Surgical Oncology International Conference on Surgical Cancer Care Meeting “The Evolution of Novel Combination Immunotherapies – Intralesional Treatments and New Targets for Treatment” Session"
  },
  {
    "objectID": "presentations/RME_Collaborative_2023/CSCC/index.html",
    "href": "presentations/RME_Collaborative_2023/CSCC/index.html",
    "title": "Integrating Novel Treatment Approaches for Cutaneous Squamous Cell Carcinoma",
    "section": "",
    "text": "Event\nRME Collaborative Oncology Congress\n\n\nOverview & Learning Objectives\n\nSummarize the clinical evidence for the efficacy and safety of new and emerging therapeutic options and treatment strategies for cutaneous squamous cell carcinoma (CSCC)\nDevelop individualized management plans for advanced and metastatic CSCC, incorporating current guideline recommendations, clinical data, and best practices\nImplement evidence-based strategies for reducing disparities in CSCC care and treatment in rural and underserved settings"
  },
  {
    "objectID": "presentations/RME_Collaborative_2023/BCC/index.html",
    "href": "presentations/RME_Collaborative_2023/BCC/index.html",
    "title": "Integrating the Latest Evidence on Management of Basal Cell Carcinoma",
    "section": "",
    "text": "Event\nRME Collaborative Oncology Congress\n\n\nOverview & Learning Objectives\n\nImplement evidence-based strategies for reducing disparities in basal cell carcinoma (BCC) care in rural and underserved settings\nDifferentiate treatment options for BCC based on clinical efficacy and safety data\nIntegrate clinical evidence and current guideline recommendations into treatment plans for patients with BCC\nRecognize adverse events associated with therapies for BCC to improve adherence to therapy"
  },
  {
    "objectID": "presentations.html",
    "href": "presentations.html",
    "title": "Presentations",
    "section": "",
    "text": "Members of the SoCO community contribute to the field of cutaneous oncology in a myriad of ways, including scientific investigation and medical education. Here, we highlight past and upcoming presentations by SoCO members at local, regional, national and international events."
  },
  {
    "objectID": "presentations.html#mcgi",
    "href": "presentations.html#mcgi",
    "title": "Presentations",
    "section": "MCGI",
    "text": "MCGI\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\nNovel Approaches to RAS Targeting\n\n\n\n\n\n\n\n2023\n\n\nMCGI\n\n\n\n\nDiscussion of novel approaches to targeting the RAS pathway\n\n\n\n\n\n\nApr 1, 2023\n\n\nRyan J. Sullivan\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "presentations.html#rme-collaborative-oncology-congress",
    "href": "presentations.html#rme-collaborative-oncology-congress",
    "title": "Presentations",
    "section": "RME Collaborative Oncology Congress",
    "text": "RME Collaborative Oncology Congress\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\nIntegrating Novel Treatment Approaches for Cutaneous Squamous Cell Carcinoma\n\n\n\n\n\n\n\n2023\n\n\nOncology Congress\n\n\nCSCC\n\n\n\n\nWe summarize the clinical evidence for the efficacy and safety of new and emerging therapeutic options and treatment strategies for cutaneous squamous cell carcinoma\n\n\n\n\n\n\nApr 1, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\n  \n\n\n\n\nIntegrating the Latest Evidence on Management of Basal Cell Carcinoma\n\n\n\n\n\n\n\n2023\n\n\nOncology Congress\n\n\nBCC\n\n\n\n\nWe discuss implementation of evidence-based strategies for reducing disparities in basal cell carcinoma (BCC) care in rural and underserved settings\n\n\n\n\n\n\nMar 31, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "presentations.html#society-of-surgical-oncology-2023-international-conference",
    "href": "presentations.html#society-of-surgical-oncology-2023-international-conference",
    "title": "Presentations",
    "section": "Society of Surgical Oncology 2023 International Conference",
    "text": "Society of Surgical Oncology 2023 International Conference\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\nIntralesional Treatments for Cancer\n\n\n\n\n\n\n\n2023\n\n\nSSO\n\n\n\n\nUpdates on the advancements of intralesional treatments for Cancer.\n\n\n\n\n\n\nMar 23, 2023\n\n\nHoward L Kaufman\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "presentations.html#american-academy-of-dermatology-2023-annual-meeting",
    "href": "presentations.html#american-academy-of-dermatology-2023-annual-meeting",
    "title": "Presentations",
    "section": "American Academy of Dermatology 2023 Annual Meeting",
    "text": "American Academy of Dermatology 2023 Annual Meeting\n\n\n   \n     \n     \n       Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n  \n\n\n\n\nRespect the Dormant Beast: Optimize Your Management of High-risk Cutaneous SCCs\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nCSCC\n\n\n\n\nPearls on the current concepts in management of high-risk CSCC\n\n\n\n\n\n\nMar 20, 2023\n\n\nVishal A. Patel\n\n\n\n\n\n\n  \n\n\n\n\nVolunteering Abroad, A Surgical Perspective\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\n\n\nPearls for surgeons volunteering abroad\n\n\n\n\n\n\nMar 20, 2023\n\n\nVishal A. Patel\n\n\n\n\n\n\n  \n\n\n\n\nExploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma\n\n\n\n\n\n\n\n2023\n\n\nCSCC\n\n\n\n\nThis live program explores key clinical practice insights for patients with advanced cutaneous squamous cell carcinoma\n\n\n\n\n\n\nMar 19, 2023\n\n\nDavid M. Miller, Vishal A. Patel\n\n\n\n\n\n\n  \n\n\n\n\nA non-invasive, adhesive patch gene expression test is safe and cost effective for melanoma screening: CON?\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nWe engage in a debate regarding screening for melanoma with some of the latest technologies.\n\n\n\n\n\n\nMar 19, 2023\n\n\nLaura K Ferris\n\n\n\n\n\n\n  \n\n\n\n\nMultidisciplinary Management of Melanoma and Merkel Cell Carcinoma\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\nMerkel Cell Carcinoma\n\n\n\n\nPearls on multi-disciplinary management of melanoma and Merkel cell carcinoma\n\n\n\n\n\n\nMar 18, 2023\n\n\nVishal A. Patel\n\n\n\n\n\n\n  \n\n\n\n\nUpdate on the Latest Advances in Treatment of Melanoma\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nPearls on the latest advances in the treatment of melanoma\n\n\n\n\n\n\nMar 18, 2023\n\n\nVernon Sondak\n\n\n\n\n\n\n  \n\n\n\n\nUpdates in Merkel Cell Carcinoma\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMerkel Cell Carcinoma\n\n\n\n\nPearls on the current concepts in diagnosis and management of MCC\n\n\n\n\n\n\nMar 18, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\n  \n\n\n\n\nManagement of High Risk Uncommon Cutaneous Neoplasms\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMerkel Cell Carcinoma\n\n\n\n\nPearls on the current concepts in diagnosis and management of uncommon cutaneous neoplasms\n\n\n\n\n\n\nMar 17, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\n  \n\n\n\n\nManagement of Operable Advanced NMSC\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nBCC\n\n\nCSCC\n\n\n\n\nPearls on the current concepts in diagnosis and management of operable non-melanoma skin cancer\n\n\n\n\n\n\nMar 17, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\n  \n\n\n\n\nUpdate in Advanced Melanoma Therapy\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nPearls on the latest in melanoma therapy\n\n\n\n\n\n\nMar 17, 2023\n\n\nLaura Ferris\n\n\n\n\n\n\n  \n\n\n\n\nLessons learned from resident selection and recruitment\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\n\n\nLessons learned about DEI from resident selection and recruitment\n\n\n\n\n\n\nMar 17, 2023\n\n\nMayra Lorenzo MD, PhD, FAAD\n\n\n\n\n\n\n  \n\n\n\n\nHow do we implement systemic therapy to reduce recurrence of high-risk melanomas: from neoadjuvant to adjuvant therapy?\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nPearls on the current concepts in peri-operative management of high-risk melanoma\n\n\n\n\n\n\nMar 17, 2023\n\n\nDavid M. Miller\n\n\n\n\n\n\n  \n\n\n\n\nHow can we improve detection and reduce unnecessary biopsies: from dermoscopy to artificial intelligence to non-invasive molecular testing?\n\n\n\n\n\n\n\n2023\n\n\nAAD Meeting\n\n\nMelanoma\n\n\n\n\nPearls on the current concepts in improving detection of melanoma\n\n\n\n\n\n\nMar 17, 2023\n\n\nLaura K Ferris\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "jc.html#september",
    "href": "jc.html#september",
    "title": "Journal Club",
    "section": "September",
    "text": "September\nVanderWalde, Ari, Shay L. Bellasea, Kari L. Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, et al. 2023. “Ipilimumab with or Without Nivolumab in PD-1 or PD-L1 Blockade Refractory Metastatic Melanoma: A Randomized Phase 2 Trial.” Nature Medicine, August. https://doi.org/10.1038/s41591-023-02498-y.\n\nAugust\nBecker, Jürgen C, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian Haferkamp, Lisa Zimmer, et al. 2023. “Adjuvant Immunotherapy with Nivolumab Versus Observation in Completely Resected Merkel Cell Carcinoma (ADMEC-O): Disease-Free Survival Results from a Randomised, Open-Label, Phase 2 Trial.” The Lancet, July. https://doi.org/10.1016/s0140-6736(23)00769-9.\n\n\nJuly\nDieng, Mbathio, Sarah J. Lord, Robin M. Turner, Omgo E. Nieweg, Alexander M. Menzies, Robyn P. M. Saw, Andrew J. Einstein, et al. 2022. “The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.” Annals of Surgical Oncology 29 (5): 2871–81. https://doi.org/10.1245/s10434-021-11231-3.\n\n\nJune\nMangione, Carol M., Michael J. Barry, Wanda K. Nicholson, David Chelmow, Tumaini Rucker Coker, Esa M. Davis, Katrina E. Donahue, et al. 2023. “Screening for Skin Cancer.” JAMA 329 (15): 1290. https://doi.org/10.1001/jama.2023.4342.\n\n\nMay\nDrobni, Zsofia D., Raza M. Alvi, Jana Taron, Amna Zafar, Sean P. Murphy, Paula K. Rambarat, Rayma C. Mosarla, et al. 2020. “Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.” Circulation 142 (24): 2299–2311. https://doi.org/10.1161/circulationaha.120.049981.\n\n\nApril\nPatel, Sapna P., Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, et al. 2023. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine 388 (9): 813–23.\n\n\nMarch\nAllen, Nicholas C., Andrew J. Martin, Victoria A. Snaidr, Renee Eggins, Alvin H. Chong, Pablo Fernandéz-Peñas, Douglas Gin, et al. 2023. “Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.” New England Journal of Medicine 388 (9): 804–12. https://doi.org/10.1056/nejmoa2203086.\n\n\nFebruary\nAscierto, Paolo A, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, et al. 2023. “Overall Survival with First-Line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study.” The Lancet Oncology 24 (1): 33–44. https://doi.org/10.1016/s1470-2045(22)00687-8.\n\n\nJanuary\nRohaan, Maartje W., Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, et al. 2022. “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.” New England Journal of Medicine 387 (23): 2113–25. https://doi.org/10.1056/nejmoa2210233."
  },
  {
    "objectID": "research_forum/Prognostic Significant of Initial AMERK for MCC/index.html",
    "href": "research_forum/Prognostic Significant of Initial AMERK for MCC/index.html",
    "title": "Prognostic Significant of AMERK Serostatus in MCC",
    "section": "",
    "text": "Event\nSociety of Cutaneous Oncology Research Forum\n\n\nOverview & Learning Objectives\n\nWe review results from a dual-institutional observation study of patients with Merkel Cell Carcinoma who underwent Merkel Cell Polyoma Virus antibody testing within 90 days of diagnosis."
  },
  {
    "objectID": "research_forum.html#overview",
    "href": "research_forum.html#overview",
    "title": "Research Forum",
    "section": "",
    "text": "In an effort to fulfill our missions of 1) supporting SoCO members in producing high-quality, reproducible science and 2) educating future generations of clinical oncologists and scientific investigators dedicated to skin cancer, the Society of Cutaneous Oncology supports an open forum for research discussions and presentations that convenes several times per year."
  },
  {
    "objectID": "research_forum/Prognostic Significance of Initial AMERK for MCC/index.html",
    "href": "research_forum/Prognostic Significance of Initial AMERK for MCC/index.html",
    "title": "Prognostic Significance of AMERK Serostatus in MCC",
    "section": "",
    "text": "Event\nSociety of Cutaneous Oncology Research Forum\n\n\nOverview & Learning Objectives\n\nWe review results from a dual-institutional observation study of patients with Merkel Cell Carcinoma who underwent Merkel Cell Polyoma Virus antibody testing within 90 days of diagnosis."
  },
  {
    "objectID": "research_forum/Prognostic Significance of Initial AMERK Serostatus/index.html",
    "href": "research_forum/Prognostic Significance of Initial AMERK Serostatus/index.html",
    "title": "Prognostic Significance of Initial AMERK Serostatus",
    "section": "",
    "text": "Event\nSociety of Cutaneous Oncology Research Forum\n\n\nOverview & Learning Objectives\n\nWe review results from a dual-institutional observation study of patients with Merkel Cell Carcinoma who underwent Merkel Cell Polyoma Virus antibody testing within 90 days of diagnosis."
  },
  {
    "objectID": "jc.html#articles-6",
    "href": "jc.html#articles-6",
    "title": "Journal Club",
    "section": "2019 Articles",
    "text": "2019 Articles\n\n\n\n\n\n\nApril - December 2019\n\n\n\n\n\n\nDecember\nKnepper, Todd C., Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, et al. 2019. “The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.” Clinical Cancer Research 25 (19): 5961–71. https://doi.org/10.1158/1078-0432.ccr-18-4159.\n\n\nNovember\nHarris, Brianna N., Patrik Pipkorn, Ky Nam Bai Nguyen, Ryan S. Jackson, Shyam Rao, Michael G. Moore, D. Gregory Farwell, and Arnaud F. Bewley. 2019. “Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.” JAMA OtolaryngologyHead & Neck Surgery145 (2): 153. https://doi.org/10.1001/jamaoto.2018.3650.\nStrassen, Ulrich, Benedikt Hofauer, Christian Jacobi, and Andreas Knopf. 2016. “Management of Locoregional Recurrence in Cutaneous Squamous Cell Carcinoma of the Head and Neck.” European Archives of Oto-Rhino-Laryngology 274 (1): 501–6. https://doi.org/10.1007/s00405-016-4243-7.\n\n\nOctober\nMigden, Michael R., Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, et al. 2018. “PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.” New England Journal of Medicine 379 (4): 341–51. https://doi.org/10.1056/nejmoa1805131.\n\n\nSeptember\nFox, Matthew, Marc Brown, Nicholas Golda, Dori Goldberg, Christopher Miller, Melissa Pugliano-Mauro, Chrysalyne Schmults, et al. 2019. “Nodal Staging of High-Risk Cutaneous Squamous Cell Carcinoma.” Journal of the American Academy of Dermatology 81 (2): 548–57. https://doi.org/10.1016/j.jaad.2018.09.006.\n\n\nAugust\nRuiz, Emily Stamell, Pritesh S. Karia, Robert Besaw, and Chrysalyne D. Schmults. 2019. “Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition Vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma.” JAMA Dermatology 155 (7): 819. https://doi.org/10.1001/jamadermatol.2019.0032.\n\n\nJuly\nGore, Sinclair M., Douglas Shaw, Richard C. W. Martin, Wendy Kelder, Kathryn Roth, Roger Uren, Kan Gao, et al. 2015. “Prospective Study of Sentinel Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.” Head & Neck 38 (S1): E884–89. https://doi.org/10.1002/hed.24120.\n\n\nJune\nMiller, Natalie J., Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, et al. 2018. “Merkel Cell Polyomavirus-Specific Immune Responses in Patients with Merkel Cell Carcinoma Receiving Anti-PD-1 Therapy.” Journal for ImmunoTherapy of Cancer 6 (1). https://doi.org/10.1186/s40425-018-0450-7.\n\n\nMay\nRosenberg, Abby R., Mary Tabacchi, Kenneth H. Ngo, Michael Wallendorf, Ilana S. Rosman, Lynn A. Cornelius, and Shadmehr Demehri. 2019. “Skin Cancer Precursor Immunotherapy for Squamous Cell Carcinoma Prevention.” JCI Insight 4 (6). https://doi.org/10.1172/jci.insight.125476.\n\n\nApril\nPorceddu, Sandro Virgilio, Mathias Bressel, Michael Geoffrey Poulsen, Adam Stoneley, Michael John Veness, Lizbeth Moira Kenny, Chris Wratten, et al. 2018. “Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.” Journal of Clinical Oncology 36 (13): 1275–83. https://doi.org/10.1200/jco.2017.77.0941."
  },
  {
    "objectID": "jc.html#february",
    "href": "jc.html#february",
    "title": "Journal Club",
    "section": "February",
    "text": "February\nDeCamp, Matthew, Julie Ressalam, Hillary D. Lum, Elizabeth R. Kessler, Dragana Bolcic-Jankovic, Vinay Kini, and Eric G. Campbell. 2023. “Ethics and Medical Aid in Dying: Physicians’ Perspectives on Disclosure, Presence, and Eligibility.” Journal of Law, Medicine & Ethics 51 (3): 641–50. DOI: 10.1017/jme.2023.1001\n\nJanuary\nMcEvoy, Aubriana M., Daniel S. Hippe, Kristina Lachance, Song Park, Kelsey Cahill, Mary Redman, Ted Gooley, Michael W. Kattan, and Paul Nghiem. 2023. “Merkel Cell Carcinoma Recurrence Risk Estimation Is Improved by Integrating Factors Beyond Cancer Stage: A Multivariable Model and Web-Based Calculator.” Journal of the American Academy of Dermatology, November. https://doi.org/10.1016/j.jaad.2023.11.020."
  }
]